# Auto Stem Cell Transplant for Lymphoma Patients

> **NCT03125642** · PHASE2 · RECRUITING · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 150 (estimated)

## Conditions studied

- Non-Hodgkin Lymphoma
- Hodgkin Lymphoma

## Interventions

- **DRUG:** Etoposide
- **DRUG:** BCNU
- **DRUG:** AraC
- **DRUG:** Melphalan
- **PROCEDURE:** Peripheral blood stem cell transplantation
- **BIOLOGICAL:** G-CSF
- **DRUG:** Cyclophosphamide
- **RADIATION:** Total Body Irradiation

## Key facts

- **NCT ID:** NCT03125642
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-04-20
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03125642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03125642, "Auto Stem Cell Transplant for Lymphoma Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03125642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*